Skip to main content

Table 3 Number of oocytes and total gonadotrophin dose for hMG versus r-hFSH

From: Recombinant human follicle-stimulating hormone produces more oocytes with a lower total dose per cycle in assisted reproductive technologies compared with highly purified human menopausal gonadotrophin: a meta-analysis

Studied endpoint for hMG versus r-hFSH

MD

95% CI

p value

SDM

95% CI

P value

Number of oocytes

      

   - Main analysis

-1.54

-2.53, -0.56

< 0.0001

-0.23

-0.36, -0.10

< 0.0001

   - Sub-group 1

-1.68

-2.69, -0.68

< 0.0001

-0.25

-0.38, -0.12

< 0.0001

   - Sub-group 2

-1.57

-2.65, -0.49

< 0.001

-0.24

-0.38, -0.11

< 0.0001

   - Main analysis (fixed model)

-1.74

-2.12, -1.35

< 0.0001

-0.26

-0.32, -0.19

< 0.0001

Number of oocytes adjusted for baseline

-2.10

-2.83, -1.36

< 0.001

-0.35

-0.47, -0.22

< 0.0001

Dosage (IU)

235.46

16.62, 454.30

0.03

0.33

0.08, 0.58

0.01

  1. hMG = human menopausal gonadotrophins; r-hFSH = recombinant human follicle-stimulating hormone; MD = mean difference; SDM = standardized mean difference